The bottom line: We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades.

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Markets fared ...

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by Morningstar users in February 2026. Given February was earnings season, the trends ...

Here's what to expect from the Biotech stock next. The post 3 reasons why the CSL share price could leap 87% to $274! appeared first on The Motley Fool Australia.

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more surprising. The post What on earth's going on with the CSL share price? appeared ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...